Abstract
THERE is evidence for the existence of multiple forms of dopamine (DA) receptors1–3. In particular, some of these receptors are coupled to adenylate cyclase (DA-stimulating enzyme activity), whereas others seem to be independent3–5. These two classes of receptors, which have been designated D-1 and D-2, respectively, would also have different pharmacological properties3. Pituitary mammotroph DA receptors regulating prolactin (PRL) secretion are considered to be typical D-2 receptors. A DA-stimulated adenylate cyclase has not been detected in normal anterior pituitaries3,5,6; furthermore, several studies indicate that cyclic AMP is stimulatory and not inhibitory to PRL secretion7,8. We report here that in homogenates of human PRL adenomas, in which dopaminergic agonists act as inhibitors of PRL secretion, basal adenylate cyclase is inhibited by DA. The DA receptors mediating this inhibition have the same pharmacological properties as those regulating PRL secretion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cools, A. R. & Van Rossum, J. M. Psychopharmacologia 45, 243–254 (1976).
Creese, J., Burt, D. R. & Snyder, S. H. Life Sci. 17, 993–1002 (1975).
Kebabian, J. W. & Calne, D. B. Nature 277, 93–96 (1979).
Kebabian, J. W., Petzold, G. L. & Greengard, P. Proc. natn. Acad. Sci. U.S.A 69, 2145–2149 (1972).
Spano, P. F., Govoni, S. & Trabucchi, M. Adv. Biochem. Psychopharmac. 19, 155–166 (1977).
Schmidt, M. G. & Hill, L. E. Life Sci. 20, 789–797 (1977).
Hill, M. K., MacLeod, R. M. & Orcutt, P. Endocrinology 99, 1612–1617 (1976).
Labrie, F. et al. in Advances in Cyclic Nucleotide Res. Vol. 5 (eds Drummond, G. I.,Geengard, P. & Robison, G. A.) 787–801 (Raven, New York, 1975).
Maizel, J. V. Jr in Methods in Virology, Vol 5 (eds Maramorosch, K. & Koprowski, H.) 179–244 (Academic, New York, 1971).
Fluckiger, E. et al. Experientia 34, 1330–1332 (1978).
Calabro, M. A. & MacLeod, R. M. Neuroendocrinology 25, 32–46 (1978).
Cronin, M. J., Roberts, J. M. & Weiner, R. I. Endocrinology 103, 302–309 (1978).
Caron, M. G. et al. J. biol. Chem. 253, 2244–2253 (1978).
MacLeod, R. M. & Robyn, C. J. Endocr. 72, 273–277 (1977).
Crosignani, P. G. et al. J. clin. Endocr. Metab. 45, 841–844 (1977).
Clement-Cormier, Y. C., Heindel, J. J. & Robison, G. A. Life Sci. 21, 1357–1364 (1977).
Rudolph, S. A., Beam, K. G. & Greengard, P. in Membrane Transport Processes Vol. 1 (ed. Hoffman, J. F.) 107–123 (Raven, New York, 1978).
Jard, S., Roy, C., Barth, T., Rajerison, R. & Bockaert, J. in Advances in Cylic Nucleotide Research Vol. 5 (eds Drummond, G. J., Greengard, P. & Robison, G. A.) 31–52 (Raven, New York, 1975).
Brown, E. M., Gardner, D. G., Windeck, R. A. & Aurbach, G. D. Endocrinology 103, 2323–2333 (1978).
Cheung, C. J. & Weiner, R. I. Endocrinology 102, 1614–1620 (1978).
Carlsson, A. in Pre- and Postsynaptic Receptors (eds Usdin, E. and Bunney, W. E.) 49–65 (Marcel Dekker, New York, 1975).
Di Chiara, G., Vargiu, L., Porceddu, M. L. & Gessa, G. L. Adv. Biochem. Psychopharmac. 16, 443–447 (1977).
Di Chiara, G., Corsini, G. U., Mereu, G. P., Tissari, A. & Gessa, G. L. Adv. Biochem. Psychopharmac. 19, 275–292 (1978).
Ebstein, B., Roberge, C., Tabachnik, J. & Goldstein, M. J. Pharm. Pharmac. 26, 975–977 (1974).
Harris, G. E., Morgenroth, V. H., Roth, R. H. & Baldessarini, R. J. Nature 252, 156–158 (1974).
Roth, P. H., Walters, J. R., Murrin, L. C. & Morgenroth, V. H. III in Pre- and Postsynaptic Receptors (eds Usdin, E. & Bunney, W. E.) 5–48 (Marcel Dekker, New York, 1974).
Salomon, Y., Londos, C. & Rodbell, M. Analyt. Biochem. 58, 541–548 (1974).
Sinha, Y. N., Selby, F. W., Lewis, V. F. & Vanderlaan, W. P. J. clin. Endocr. Metab. 36, 509–516 (1973).
Lowry, O. H., Rosenbrough, N. J., Farr, A. L. & Randall, R. J. J. biol. Chem. 193, 265–275 (1951).
Mulder, G. H. & Smelik, P. G. Endocrinology 100, 1143–1152 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DE CAMILLI, P., MACCONI, D. & SPADA, A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278, 252–254 (1979). https://doi.org/10.1038/278252a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/278252a0
This article is cited by
-
How changes in dopamine D2 receptor levels alter striatal circuit function and motivation
Molecular Psychiatry (2022)
-
Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas
Pituitary (2017)
-
Current perspectives on the selective regulation of dopamine D2 and D3 receptors
Archives of Pharmacal Research (2010)
-
Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline
Pituitary (2008)
-
Pituitary development and physiology
Pituitary (2007)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.